自我免疫疾病相關生物製劑的處方動向 是由出版商Datamonitor在2009年03月所出版的。
這份英文市場調查報告書包含137 pages 價格從美金3800起跳。
本報告書內容包括：全球7大市場的醫師及意見領袖調查、自我免疫疾病治療中使用的品牌藥動向及處方動向等。內容綱要摘記如下：
實施概要
醫師動向及問卷設計
- 調查對象醫師
- 問卷設計
- 醫師人口統計
- 風濕性關節炎專門醫師
- 皮膚科專門醫師
- 胃腸科專門醫師
影響醫師決策的因素
- 影響處方決定的主要因素重要性比較
- 國別、醫師別動向
- 對醫師而言的差異
- 美國及英國具有共通性，但日本除了風濕性關節炎之外都有所差異
- 處方因素
品牌動向
- 品牌概要
- 品牌銷售動向
- 品牌認知度
- 品牌評價比較
- 品牌別分數以Humira最有發展潛力
- 國別品牌分數動向
- 品牌介紹
- 產品線藥介紹
- 針對腫瘤壞死因子（TNF）的抗體醫薬
- 其他產品線藥機制
- Stelara
- Actemra
參考資料
圖表
Abstract
Introduction
Factors influencing a prescribing decision can diverge from clinical facts. In
the highly competitive autoimmune area, misconceptions and physician habits
can result in loss of sales. Targeted detailing of specialist physicians,
differentiating by indications is the key to success. Datamonitor has surveyed
gastroenterologists, rheumatologists and dermatologists on attribute and brand
perceptions.
Scope of this research
- Opinion from 540 physicians including rheumatologists, dermatologists and
gastroenterologists is included
- Physicians and opinion leaders across the seven major markets of the US,
Japan, France, Germany, Spain, Italy and the UK
- Analysis of the extent to which certain factors affect physician
prescribing, with comparison across each specialty
- Analysis of the opinion dynamics for the key brands used across prominent
autoimmune diseases
Research and analysis highlights
Efficacy and safety factors will always be any physician' s main consideration,
drawing an average of 62% of the weighting by importance when prescribing a
biologic therapy. Actemra' s positive perception from rheumatologists, despite
known side-effects, exemplifies the importance of informing physicians about
issues, rather than masking them.
New TNF inhibitors in autoimmune disease battle against ' me-too' status and
the strong positive opinion of the existing three products in the category.
Humira leads the group with a total score 16% above the average. Newcomer
anti-TNF options Simponi (golimumab) and Cimzia (certolizumab) are not well
perceived by EU prescribing rheumatologists.
Dermatologists' exhibit cynicism towards biologic therapies, scoring all
brands lower than other physician types, less surprising when considering the
nature of most psoriasis therapies. However, Centocor' s Stelara (ustekinumab)
is highly anticipated with dermatologists scoring it 40% above average in
terms of predicted efficacy.
Key reasons to purchase this research
- Target physicians more efficiently by understanding the differences in
brand perception between physician specialties
- Tailor your marketing message to the attributes most important to
prescribing physicians
- Assess the regional dynamics of physician perception in autoimmune disease
across the seven major markets
Table of Contents
EXECUTIVE SUMMARY
- Datamonitor insight into the autoimmune biologics market
- Contributing experts
- Related reports
- Upcoming 2009 reports
PHYSICIAN DYNAMICS AND QUESTIONNAIRE DESIGN
- Physician types surveyed
- Questionnaire design
- Importance of attributes
- Rating of brands
- Physician demographics
- Rheumatologists
- Dermatologists
- Gastroenterologists
FACTORS INFLUENCING PHYSICIAN DECISION MAKING
- Comparative importance of factors to the prescribing decision
- Disease modification and side-effects are the most important factors to
all prescribing physicians
- Variation by country and physician type
- Little variation seen between physician type
- The UK and US show commonality while Japan is still an outlier in all
but rheumatology
- Prescribing factors
- Efficacy
- Side effects
- Formulary or reimbursement status
- Marketing and familiarity
BRAND DYNAMICS
- Brand overview
- Brand sales trends
- Biologic sales overview shows Enbrel leads in terms of total brand sales
for all indications
- Brand awareness
- Trends in preliminary brand scores by physician type
- Brand assessment comparisons
- Total score by brand shows future promise for Humira
- Trends in brand scores by country
- Brand profiles
- Enbrel (etanercept; Amgen, Wyeth)
- Remicade (infliximab; Centocor, Schering-Plough, Mitsubishi Tanabe)
- Humira (adalimumab; Abbott)
- Orencia (abatacept; Bristol-Myers Squibb)
- Rituxan/MabThera (rituximab; Roche, Genentach, Biogen Idec)
- Raptiva (efalizumab; Genentech, Xoma, Merck Serono)
- Amevive (alfacept; Astellas, Biogen Idec)
- Tysabri (natalizumab; Biogen Idec, Elan)
- Pipeline profiles
- Pipeline overview
- Licensing opportunities
- Pipeline anti-TNFs
- The three available anti-TNFs are perceived to be similar, but pipeline
anti-TNFs offer little apparent improvement
- Cimzia (certolizumab; UCB)
- Simponi (golimumab; Centocor, Schering-Plough, Mitsubishi Tanabe,
Janssen)
- Other pipeline mechanisms
- Stelara (ustekinumab; Centocor, Janssen Cilag)
- Actemra (tocilizumab; Chugai, Roche)
BIBLIOGRAPHY
TABLES
- Table: Physician type surveyed
- Table: Comparison of physician demographics
- Table: Characteristics of rheumatologists surveyed across the seven major
markets, 2008
- Table: Characteristics of dermatologists surveyed across the seven major
markets, 2008
- Table: Characteristics of gastroenterologists surveyed across the seven
major markets, 2007
- Table: Attributes assessed by each physician type
- Table: Anti-TNF prescribing information efficacy comparison across
indications
- Table: Other mechanism prescribing information efficacy data
- Table: Summary of pros and cons of biomarkers to predict response to TNF
therapy
- Table: Summary of prescribing information black box and major warnings by
brand
- Table: Percent of patients showing positive antibodies against each brand
according to prescribing information
- Table: Formulary prices across the seven major markets, 2008
- Table: Importance of dosing frequency and delivery method to prescribing
of biologics, by country and by physician specialty, %
- Table: Overview of brand details including mechanism, indications and
launch dates
- Table: Number and percent of physicians able to rate each brand, by country
- Table: Score given to each brand by attribute, by rheumatologists, 2008
- Table: Score given to each brand by attribute, by dermatologists, 2008
- Table: Score given to each brand by attribute, by gastroenterologist, 2007
- Table: Brand scores by country
- Table: Enbrel' s attribute scores, by country and physician type
- Table: Remicade' s attribute score, by country and physician type
- Table: Humira' s scores by country, attribute and physician type
- Table: Orencia' s scores from rheumatologists by country
- Table: Rituxan/MabThera' s scores, from rheumatologists by country
- Table: Raptiva' s scores by attribute and country, from dermatologists
- Table: Amevive scores by country and attribute, from dermatologists
- Table: Tysabri scores by country and attribute, from gastroenterologists
- Table: Antibody products in clinical trials for autoimmune diseases
(rheumatoid arthritis, inflammatory bowel disease, psoriasis)
- Table: Late stage pipeline product profiles and status by indication and
region
- Table: Cimzia' s attribute scores by country and physician type
- Table: Simponi scores by country and attribute, from rheumatologists
- Table: Stelara scores by country and attribute, from dermatologists
- Table: Actemra scores by country and attribute, from rheumatologists
FIGURES
- Figure: Grouped attribute average importance
- Figure: Attribute importance, split by physician type
- Figure: Average attribute importance to prescribing decision for biologic
therapies, by country
- Figure: Importance of grouped attributes to the prescribing decision by
physician specialty
- Figure: Mapping country dynamics with reference to attribute importance,
split by physician type
- Figure: Importance of efficacy factors to prescribing decision for
biologic therapies, by country and specialist
- Figure: Biologic comparative brand scores for efficacy factors, by
physician type
- Figure: Speed of action scores by dermatologists and gastroenterologists,
non-weighted
- Figure: Importance of a good side-effect profile to prescribing decision
for biologic therapies, by country and specialist
- Figure: Importance of formulary and reimbursement status to prescribing
decision for biologic therapies, by country and specialist
- Figure: Brand comparison scores for formulary/reimbursement status, by
physician type
- Figure: Ankylosing spondylitis treatment tree, 2008, seven major markets
- Figure: Importance of dosing frequency and delivery method to prescribing
of biologic, by country and by physician specialty
- Figure: Brand scores comparison for administration attributes
- Figure: Importance of marketing and familiarity to prescribing of
biologics, by country and by physician specialty
- Figure: Representation of influences of prescribing
- Figure: Total representative count, 2003 - 2007
- Figure: Brand scores comparison for marketing and familiarity attributes
- Figure: Time on the market versus score for marketing/familiarity factors
- Figure: Humira' s website messages
- Figure: Enbrel' s directed messages for each indication
- Figure: Remicade' s US website messages
- Figure: Online marketing for non-TNF mechanisms
- Figure: Total brand sales for the top autoimmune biologics in the US, five
major EU markets and Japan, $m, 2007
- Figure: Total brand sales across the seven major markets, split by
indication, $bn, 2007
- Figure: Sales growth versus market share by indication for the major
biologic brands in the seven major markets, 2004 - 07
- Figure: Percentage of physicians able to rate each brand, by country
- Figure: Sum of score for all attributes, by brand and physician type
- Figure: Average score for each of the eight comparable attributes, by brand
- Figure: Overview brand map of attributes versus brand perception by
physician specialty
- Figure: Average weighted brand scores by attribute
- Figure: Brand scores by country
- Figure: Enbrel' s weighted score compared to average
- Figure: Enbrel map, country preference to prescribing attributes
- Figure: Remicade' s weighted score compared to the average
- Figure: Remicade map, country preference to prescribing attributes
- Figure: Humira' s weighted score compared to the average
- Figure: Humira map, country preference for prescribing attributes
- Figure: Orencia' s weighted scores compared to all physicians average
scores and rheumatologists average
- Figure: Rituxan/MabThera' s weighted scores compared to all physicians
average scores and rheumatologists average
- Figure: Raptiva' s weighted score compared to all physicians average scores
and dermatologists average
- Figure: Amevive weighted score compared to all physicians average scores
and dermatologists average
- Figure: Tysabri weighted score compared to all physicians average scores
and gastroenterologist average
- Figure: Phase I to pre-registration projects in the pipeline, split by
mechanism, 2009
- Figure: Comparative physician perception of the pipeline and marketed
anti-TNF inhibitors
- Figure: Cimzia' s weighted score compared to the average
- Figure: Cimzia map, country preference for prescribing attributes
- Figure: Simponi (golimumab) weighted score compared to the average
- Figure: Stelara' s weighted score compared to all physicians' average
scores and dermatologists' average
- Figure: Actemra' s weighted score compared to all physicians average scores
and rheumatologist average
|
